The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
Détails
ID Serval
serval:BIB_4D09B307B176
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
Périodique
Thrombosis and haemostasis
ISSN
0340-6245 (Print)
ISSN-L
0340-6245
Statut éditorial
Publié
Date de publication
08/1997
Peer-reviewed
Oui
Volume
78
Numéro
2
Pages
859-863
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Resistance to activated protein C (APC) has been recently identified as a common abnormality of the clotting system that significantly increases the risk of venous thromboembolism. The distribution of plasma response to APC in the general population and the variables potentially influencing it are however unknown. In this study, we analyzed the data from the first 4,000 subjects enrolled in the Vicenza Thrombophilia and Atherosclerosis (VITA) Project to identify the demographic and laboratory variables affecting the plasma response to APC. Plasma response to APC, expressed as APC-ratio, was significantly influenced not only by the presence of the FV Leiden mutation but also by the aPTT ratio, triglycerides, fibrinogen and cholesterol level and by pill use, ABO blood group, gender, smoke, body-mass index and age. The effect of these variables was independent of the presence of the FV Leiden mutation, and adjustment for their effect improved the discriminating efficiency of the APC-ratio for the presence of the FV Leiden mutation. Notwithstanding adjustment, the APC ratio was unsuitable for screening purposes in the general population (positive predictive value 82.7%).
Mots-clé
Anticoagulants/pharmacology, Cross-Sectional Studies, Drug Resistance/genetics, Factor V/genetics, Female, Humans, Male, Mutation, Protein C/pharmacology, Reference Standards
Pubmed
Web of science
Création de la notice
26/09/2023 8:53
Dernière modification de la notice
04/10/2023 13:38